As of 2:42pm ET
| -0.135 / -1.93%|
The 2 analysts offering 12-month price forecasts for Novelion Therapeutics Inc have a median target of 9.75, with a high estimate of 10.50 and a low estimate of 9.00. The median estimate represents a +41.82% increase from the last price of 6.88.
The current consensus among 2 polled investment analysts is to Outperform stock in Novelion Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.